Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience
about
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancerMelanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agentsClinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experienceCyclin alterations in diverse cancers: Outcome and co-amplification network.Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR responseClinical outcomes and survival of advanced renal cancer patients in phase I clinical trialsDeterminants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database.Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US.Phase I trial outcomes in older patients with advanced solid tumoursCharacteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience.Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies.Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit.The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials.The role of age on dose-limiting toxicities in phase I dose-escalation trials.Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experienceValidation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trialsRisks and benefits of phase 1 clinical trial participation.Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit.Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials.Effect of Age on Clinical Outcomes in Phase 1 Trial Participants.Academic Cancer Center Phase I Program Development.Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.Low skeletal muscle is associated with toxicity in patients included in phase I trials.Outcome of children and adolescents with central nervous system tumors in phase I trials.Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?Characteristics and Outcomes of Ethics Consultations in an Oncologic Intensive Care Unit.
P2860
Q33779691-35664057-8767-4B73-8D55-E0EDB84E71E2Q33845387-9C303B26-320C-4398-9422-42C1F1281357Q34646376-85B10797-FEEA-4DC0-88EB-5893219330D3Q34781347-994071E6-3619-48A3-9168-623F9C05D932Q35550165-21F90A2F-B0A9-4968-9601-ACDBA6C66CFDQ35770263-C143C3CE-FF53-41EE-AB10-E29124255B87Q35810693-49D7E586-31EA-4156-8CCA-0C57E1EDB8B5Q35820055-B4C9BCA1-93E4-4B11-8DC2-DB63CCE93DD8Q35917852-D8BBE657-705D-4543-8EC9-4C12CF457805Q36366093-E32A227E-5408-4996-A5A1-F50F9B854C3CQ36547934-2AB9C732-C292-4213-8C52-CA298AD2A8A1Q36937086-03DCCED3-4F2A-4379-ACE3-10368C807E69Q37342909-E475D6E5-612B-4554-9EB0-758473A64960Q37404400-57834425-AC64-4561-A8E5-2A106B4AA291Q37494348-C6B49CB4-1D7D-4C35-BC95-675457CB3E9BQ37552648-B4788EC8-8D9E-4E4A-B228-EC92BDC4CD9CQ37577932-F58A8BEB-8AAB-492A-931F-1ED8D455119BQ37665702-592C6EA0-5F73-4130-98F8-1799ABD4B843Q38222465-868761B0-A2EB-468F-A3E4-0EF98BDDA60CQ39226898-8C5EB858-D6C8-420C-AA19-5CA518E19E30Q39888234-54FCE516-2EC9-4E8B-BD80-24D3EE365A35Q40368139-639030F1-7702-402F-9320-5DFB7C3411F5Q40841994-FC987F48-14BB-4713-8F05-6E8450B100E0Q42046541-98FE4F82-B634-47F8-8B1A-4429807EC3FDQ43715235-AE52BE8A-623B-4225-9545-04D939AF68C1Q46520115-B978604B-C346-466A-A682-09B8C217B620Q47194256-604E0BB6-727A-42F5-AF12-C59D42C4F758Q47990284-FA7ABA33-F5F1-4B1A-8B7D-E0E5CD23D32CQ48073620-A5A33047-28E5-4FBD-9F5C-7860204284DA
P2860
Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Survival of 1,181 patients in ...... or targeted therapy experience
@ast
Survival of 1,181 patients in ...... or targeted therapy experience
@en
Survival of 1,181 patients in ...... or targeted therapy experience
@nl
type
label
Survival of 1,181 patients in ...... or targeted therapy experience
@ast
Survival of 1,181 patients in ...... or targeted therapy experience
@en
Survival of 1,181 patients in ...... or targeted therapy experience
@nl
prefLabel
Survival of 1,181 patients in ...... or targeted therapy experience
@ast
Survival of 1,181 patients in ...... or targeted therapy experience
@en
Survival of 1,181 patients in ...... or targeted therapy experience
@nl
P2093
P2860
P50
P1476
Survival of 1,181 patients in ...... or targeted therapy experience
@en
P2093
Bettzy Stephen
David Hong
Gerald Falchook
Jennifer Wheler
Sarina Piha-Paul
Stacy Moulder
P2860
P304
P356
10.1158/1078-0432.CCR-11-2217
P407
P577
2012-03-27T00:00:00Z